173 related articles for article (PubMed ID: 23828438)
41. Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling.
Kourime M; McGowan S; Al Towati M; Ahmed SF; Stewart G; Williamson S; Hunter I; Donaldson MDC
Arch Dis Child; 2018 Jul; 103(7):637-642. PubMed ID: 29269558
[TBL] [Abstract][Full Text] [Related]
42. Plasmapheresis in the therapy of hyperthyroidism associated with leukopenia.
De Rosa G; Testa A; Menichella G; Cecchini L; Cavallaro A; Mantovani M; Mango G
Haematologica; 1991 Mar; 76 Suppl 1():72-4. PubMed ID: 1713877
[TBL] [Abstract][Full Text] [Related]
43. Preoperative plasmapheresis in patients with Graves' disease intolerant to antithyroid drugs.
Apaydin T; Gogas Yavuz D
Ther Apher Dial; 2021 Dec; 25(6):877-883. PubMed ID: 33661574
[TBL] [Abstract][Full Text] [Related]
44. Transient hyperthyroidism after withdrawal of antithyroid drugs in patients with Graves' disease.
Kubota S; Tamai H; Ohye H; Fukata S; Kuma K; Miyauchi A
Endocr J; 2004 Apr; 51(2):213-7. PubMed ID: 15118273
[TBL] [Abstract][Full Text] [Related]
45. Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism.
Tomaski SM; Mahoney EM; Burgess LP; Raines KB; Bornemann M
Laryngoscope; 1997 Aug; 107(8):1066-70. PubMed ID: 9261010
[TBL] [Abstract][Full Text] [Related]
46. Propylthiouracil-induced lupus, antiphospholipid syndrome, and stroke in a patient with Graves hyperthyroidism.
Ortiz GA; Lagari-Libhaber V; Prieto-Sanchez LM; Rabinstein AA
Arch Neurol; 2011 Dec; 68(12):1587-90. PubMed ID: 22159057
[TBL] [Abstract][Full Text] [Related]
47. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
Kallner G; Vitols S; Ljunggren JG
J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
[TBL] [Abstract][Full Text] [Related]
48. Rapid preparation of severe uncontrolled thyrotoxicosis due to Graves' disease with Iopanoic acid--a case report.
Pandey CK; Raza M; Dhiraaj S; Agarwal A; Singh PK
Can J Anaesth; 2004 Jan; 51(1):38-40. PubMed ID: 14709458
[TBL] [Abstract][Full Text] [Related]
49. [Two cases of serious hepatic injury caused by antithyroid drugs].
Grzywa M; Orłowska-Florek R; Grzywa-Celińska A
Endokrynol Pol; 2009; 60(5):396-400. PubMed ID: 19885811
[TBL] [Abstract][Full Text] [Related]
50. Total Thyroidectomy for Amiodarone-induced Thyrotoxicosis in the Hyperthyroid State.
Kaderli RM; Fahrner R; Christ ER; Stettler C; Fuhrer J; Martinelli M; Vogt A; Seiler CA
Exp Clin Endocrinol Diabetes; 2016 Jan; 124(1):45-8. PubMed ID: 26575117
[TBL] [Abstract][Full Text] [Related]
51. Sepsis and thyroid storm in a patient with methimazole-induced agranulocytosis.
Nagarajan VD; Morales A; Pleasant L; Shenoi A
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32636230
[TBL] [Abstract][Full Text] [Related]
52. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease.
Poomthavorn P; Mahachoklertwattana P; Tapaneya-Olarn W; Chuansumrit A; Chunharas A
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1295-301. PubMed ID: 12549809
[TBL] [Abstract][Full Text] [Related]
53. Propylthiouracil-induced antineutrophil cytoplasmic antibodies in a patient with Graves' disease and a neutrophilic dermatosis.
Miller RM; Darben TA; Nedwich J; Savige J
Br J Dermatol; 1999 Nov; 141(5):943-4. PubMed ID: 10583195
[No Abstract] [Full Text] [Related]
54. Evaluation and Management of Children with Thyrotoxicosis.
Leung AKC; Leung AAC
Recent Pat Endocr Metab Immune Drug Discov; 2017; 11(1):22-31. PubMed ID: 29589552
[TBL] [Abstract][Full Text] [Related]
55. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
56. Controversies in the pharmacological treatment of Graves' disease in children.
De Luca F; Valenzise M
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1113-1121. PubMed ID: 30417713
[TBL] [Abstract][Full Text] [Related]
57. Severe pancytopenia associated with antithyroid drugs in a patient with Graves' disease and chronic renal failure.
Macia M; Méndez M; Fernández J; Riverol A; Rios
Clin Nephrol; 1997 Feb; 47(2):129. PubMed ID: 9049463
[No Abstract] [Full Text] [Related]
58. Therapeutic plasmapheresis for the treatment of thyrotoxicosis: A retrospective multi-center study.
Builes-Montaño CE; Rodriguez-Arrieta LA; Román-González A; Prieto-Saldarriaga C; Alvarez-Payares JC; Builes-Barrera CA; Arango-Toro CM
J Clin Apher; 2021 Oct; 36(5):759-765. PubMed ID: 34273178
[TBL] [Abstract][Full Text] [Related]
59. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome.
Sato H; Minagawa M; Sasaki N; Sugihara S; Kazukawa I; Minamitani K; Wataki K; Konda S; Inomata H; Sanayama K; Kohno Y
J Pediatr Endocrinol Metab; 2011; 24(5-6):257-63. PubMed ID: 21823520
[TBL] [Abstract][Full Text] [Related]
60. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration.
Bahn RS; Burch HS; Cooper DS; Garber JR; Greenlee CM; Klein IL; Laurberg P; McDougall IR; Rivkees SA; Ross D; Sosa JA; Stan MN
Thyroid; 2009 Jul; 19(7):673-4. PubMed ID: 19583480
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
